drugset / Trial / NCT05889442

Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab

NCT05889442

RandomizedCrossoverQuadruple-blindOther

Summary

An outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. Here, we hypothesize that experimentally-induced dilation of intracranial arteries using intravenous infusion of levcromakalim (a potent vasodilator) induces cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody).

Timeline

Start
2023-03-09
Primary completion
2023-06-12
Completion
2023-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levcromakalim Small molecule 0.05 mg Intravenous

Indications